Home > Healthcare > Pharmaceuticals > Finished Drug Form > Bone Cancer Treatment Market

Bone Cancer Treatment Market Trends

Report ID: GMI9585
Published Date: May 2024
Report Format: PDF

Download Free Sample

Bone Cancer Treatment Market Trends

As the incidence of bone cancer continues to rise globally, there is a growing demand for effective treatment options.
For instance, the American Cancer Society, estimated that approximately 3,970 new cases of primary cancer affecting the bones and joints were diagnosed in 2023. Among these cases, it is estimated that 2,160 occurred in males and 1,810 in females. Such high prevalence of bone cancers increases the demand for effective treatments, thereby driving the market growth.
Factors contributing to this increase include population aging, changes in lifestyle and environmental factors, and improved diagnostic capabilities leading to earlier detection.
Moreover, increased public awareness and education about bone cancer symptoms, results in early diagnosis and treatment, and implementation of screening programs and advancements in imaging technologies, further drives the growth of this market.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The market size of bone cancer treatment reached USD 1.2 billion in 2023 and is set to witness 5% CAGR during 2024 to 2032, led by technological advancements, and the growing focus on patient-centered care.

The primary bone cancer segment will generate USD 1.6 billion by 2032, due to its specific and complex treatment requirements.

North America market size was USD 485 million in 2023 and is projected to reach USD 741.1 million by 2032, attributed to the network of specialized cancer treatment centers.

Advaxis Inc., Amgen Inc., Atlanthera, Baxter International Inc., Bayer AG, Debiopharm, Eli Lilly and Company, Gradalis Inc., Hikma Pharmaceutical PLC, Johnson & Johnson, Novartis AG, Pfizer Inc., and Recordati Group among others.